Author: Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Nishimori, Hisashi; Ogino, Tikatoshi; Nagao, Mizuho; Fujisawa, Takao
Title: Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma Document date: 2018_8_30
ID: uzge50xu_31
Snippet: This study clearly demonstrated that preschool children with beta2-agonist responsive recurrent wheeze and multiple-trigger wheeze, a high EDN level, and HDM sensitivity responded well to both montelukast and budesonide. As expected, montelukast treatment significantly reduced sEDN levels. Unexpectedly, BIS treatment did not. Both treatments also resulted in significant decreases in rescue medication usage over the treatment period. In terms of c.....
Document: This study clearly demonstrated that preschool children with beta2-agonist responsive recurrent wheeze and multiple-trigger wheeze, a high EDN level, and HDM sensitivity responded well to both montelukast and budesonide. As expected, montelukast treatment significantly reduced sEDN levels. Unexpectedly, BIS treatment did not. Both treatments also resulted in significant decreases in rescue medication usage over the treatment period. In terms of clinical outcomes, montelukast was as effective as budesonide in the biomarkerdefined (i.e., mite sensitized, eosinophilic asthma) subpopulation of preschool asthmatics.
Search related documents:
Co phrase search for related documents- bis treatment and significant decrease: 1
- bis treatment and treatment period: 1
- budesonide montelukast and EDN level: 1
- budesonide montelukast and eosinophilic asthma: 1
- budesonide montelukast and HDM sensitivity: 1
- budesonide montelukast and montelukast treatment: 1, 2
- budesonide montelukast and multiple trigger: 1
- budesonide montelukast and multiple trigger wheeze: 1
- budesonide montelukast and recurrent wheeze: 1
- budesonide montelukast and rescue medication: 1
- budesonide montelukast and rescue medication usage: 1
- budesonide montelukast and responsive recurrent wheeze: 1
- budesonide montelukast and sEDN level: 1, 2
- budesonide montelukast and significant decrease: 1, 2
- budesonide montelukast and treatment period: 1
- clinical outcome and eosinophilic asthma: 1
- clinical outcome and montelukast treatment: 1
- clinical outcome and recurrent wheeze: 1, 2, 3
- clinical outcome and rescue medication: 1
Co phrase search for related documents, hyperlinks ordered by date